Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type

Wang,Hua; Li,Pengfei; Zhang,Xinke; Xia,Zhongjun; Lu,Yue; Huang,Huiqiang

doi:10.3892/ol.2016.4691

Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type

Authors:
- Hua Wang
- Pengfei Li
- Xinke Zhang
- Zhongjun Xia
- Yue Lu
- Huiqiang Huang
View Affiliations

Affiliations: State Key Laboratory of Oncology in South China, Sun Yat‑Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: June 9, 2016 https://doi.org/10.3892/ol.2016.4691
Pages: 825-836
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Extranodal natural killer (NK)/T‑cell lymphoma, (ENKTL), nasal type, is an aggressive lymphoma with no validated prognostic parameters, to date. In the present study, vascular invasion by this tumor was retrospectively analyzed in 214 patients with untreated ENKTL to evaluate its association with clinical features, treatment response and prognosis. Histological vascular invasion by the tumor was confirmed in 32.7% of patients with ENKTL. The presence of vascular invasion significantly correlated with poor performance status, B symptoms, extranodal involved sites, advanced stage, elevated serum lactate dehydrogenase, D‑dimer and cluster of differentiation 68+ tumor‑associated macrophages. Upon treatment termination, the complete remission (CR) rate and overall response rate were significantly lower for the vascular invasion group compared with the non‑vascular invasion group. Furthermore, vascular invasion resulted in significantly reduced 5‑year progression‑free survival (PFS; 21.8 vs. 60.1%) and overall survival (OS; 36.8 vs. 77.0%) rates. Using the multivariate Cox regression model, vascular invasion, stage III/IV and CR after chemotherapy were independent prognostic factors for OS and PFS. Thus, histological vascular invasion by the tumor affected the response to treatment, and was also an independent prognostic factor for OS and PFS in ENKTL, nasal type, suggesting a role for vascular invasion in disease progression.

View Figures

View References

1	Vose J, Armitage J and Weisenburger D: International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
2	Au WY, Ma SY, Chim CS, et al: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol. 16:206–214. 2005. View Article : Google Scholar : PubMed/NCBI
3	Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, Song YW, Lu J, Jin J, Wang SL, et al: Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 15:2905–2912. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY and Chim CS: SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 120:2973–2980. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wang L, Xia ZJ, Huang HQ, Lu Y and Zhang YJ: Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 96:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
6	Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, et al: Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol. 24:612–618. 2006. View Article : Google Scholar : PubMed/NCBI
7	Nishida T, Katayama S and Tsujimoto M: The clinicopathological significance of histologic vascular invasion in differentiated thyroid carcinoma. Am J Surg. 183:80–86. 2002. View Article : Google Scholar : PubMed/NCBI
8	Straume O and Akslen LA: Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 78:1211–1219. 1996. View Article : Google Scholar : PubMed/NCBI
9	Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J and Tateno H: Histologic features and clinical significance of venous invasion in colorectal carcinoma with hepatic metastasis. Cancer. 78:2313–2317. 1996. View Article : Google Scholar : PubMed/NCBI
10	Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y and Sugimachi K: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 128:408–416. 2000. View Article : Google Scholar : PubMed/NCBI
11	Chau GY, Lui WY and Wu CW: Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am. 12:25–34, viii. 2003. View Article : Google Scholar : PubMed/NCBI
12	Van Poppel H, Vandendriessche H, Boel K, Mertens V, Goethuys H, Haustermans K, Van Damme B and Baert L: Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol. 158:45–49. 1997. View Article : Google Scholar : PubMed/NCBI
13	Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, et al: Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 240:306–312. 2004. View Article : Google Scholar : PubMed/NCBI
14	Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ and Li ZM: Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 22:149–155. 2011. View Article : Google Scholar : PubMed/NCBI
15	Conill C, Verger E and Salamero M: Performance Status Assessment in Cancer Patients. Cancer. 65:1864–1866. 1990. View Article : Google Scholar : PubMed/NCBI
16	Musshoff K and Schmidt-Vollmer H: Proceedings: Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification. Cancer Res Clin Oncol. 83:323–341. 1975.
17	Lin ZX, Bai B, Cai QC, Cai QQ, Wang XX, Wu XY and Huang HQ: High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol. 29:3522–3528. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Xia ZJ, Huang HQ, Lu Y and Zhang YJ: Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13 year follow up in 135 patients. Int J Hematol. 96:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
19	Huijgens PC, Ossenkoppele GJ, Van Der Lelie J, Thomas LL, Wijngaarden MJ and Slaper CM: IMVP-16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma. Hematol Oncol. 9:245–251. 1991. View Article : Google Scholar : PubMed/NCBI
20	Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR and Swan F: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 71:117–122. 1988.PubMed/NCBI
21	Wang H, Wuxiao ZJ, Zhu J, Wang Z, Wang KF, Li S, Chen X, Lu Y and Xia ZJ: Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as firstline chemotherapy in patients with stage IE to IIE extranodal natural killer/Tcell lymphoma: A multicenter retrospective study. Leuk Lymphoma. 56:971–977. 2015. View Article : Google Scholar : PubMed/NCBI
22	Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol. 17:12441999.PubMed/NCBI
23	Jiang L, Li P, Wang H, Liu J, Zhang X, Qiu H and Zhang B: Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. Med Oncol. 31:2182014. View Article : Google Scholar : PubMed/NCBI
24	Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Brière J, Baglin AC, Cheze S, Bosq J, et al: Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: Results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 109:2183–2189. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, Kim DW, Heo DS and Kim CW: Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol. 20:1688–1696. 2009. View Article : Google Scholar : PubMed/NCBI
26	Shim SJ, Yang WI, Shin E, Koom WS, Kim YB, Cho JH, Suh CO, Kim JH and Kim GE: Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys. 67:31–38. 2007. View Article : Google Scholar : PubMed/NCBI
27	Hong J, Park S, Baek HL, Jung JH, Kang IG, Sym SJ, Park J, Ahn JY, Cho EK, Kim ST, et al: Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol. 5:939–947. 2012.PubMed/NCBI
28	Cuadra-Garcia I, Proulx GM, Wu CL, Wang CC, Pilch BZ, Harris NL and Ferry JA: Sinonasal lymphoma: A clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol. 23:1356–1369. 1999. View Article : Google Scholar : PubMed/NCBI
29	Seki D, Ueno K, Kurono Y and Eizuru Y: Clinicopathological features of Epstein-Barr virus-associated nasal T/NK cell lymphomas in southern Japan. Auris Nasus Larynx. 28:61–70. 2001. View Article : Google Scholar : PubMed/NCBI
30	Wróbel T, Poreba M, Mazur G, Poreba R, Pyszel A, Beck B, Steinmetz-Beck A, Andrzejak R and Kuliczkowski K: Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma. Neoplasma. 53:253–258. 2006.PubMed/NCBI
31	Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, et al: Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 intergroup trial. Blood. 120:3280–3287. 2012. View Article : Google Scholar : PubMed/NCBI
32	Siveen KS and Kuttan G: Role of macrophages in tumour progression. Immunol Lett. 123:97–102. 2009. View Article : Google Scholar : PubMed/NCBI
33	Allavena P, Sica A, Solinas G, Porta C and Mantovani A: The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit Rev Oncol Hematol. 66:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
34	Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, et al: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 24:181–189. 2006. View Article : Google Scholar : PubMed/NCBI
35	Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK and Kim BS: Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol. 18:54–63. 2000.PubMed/NCBI
36	Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, Yoon JH and Kim GE: Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 59:1127–1137. 2004. View Article : Google Scholar : PubMed/NCBI
37	Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM and Hong RL: Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 100:366–375. 2004. View Article : Google Scholar : PubMed/NCBI
38	Wang H, Wuxiao ZJ, Zhu J, Wang Z, Wang KF, Li S, Chen X, Lu Y and Xia ZJ: Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: A multicenter retrospective study. Leuk Lymphoma. 56:971–977. 2015. View Article : Google Scholar : PubMed/NCBI
39	Kim SJ, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, et al: Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 93:1895–1901. 2014. View Article : Google Scholar : PubMed/NCBI